CL2013002417A1 - Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. - Google Patents
Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.Info
- Publication number
- CL2013002417A1 CL2013002417A1 CL2013002417A CL2013002417A CL2013002417A1 CL 2013002417 A1 CL2013002417 A1 CL 2013002417A1 CL 2013002417 A CL2013002417 A CL 2013002417A CL 2013002417 A CL2013002417 A CL 2013002417A CL 2013002417 A1 CL2013002417 A1 CL 2013002417A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- pharmaceutical composition
- bacterial infections
- fluoropyridinone
- compounds derived
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449825P | 2011-03-07 | 2011-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013002417A1 true CL2013002417A1 (es) | 2013-12-13 |
Family
ID=45841548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013002417A CL2013002417A1 (es) | 2011-03-07 | 2013-08-21 | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US8624034B2 (https=) |
| EP (1) | EP2683689B1 (https=) |
| JP (1) | JP5620020B2 (https=) |
| KR (1) | KR101593288B1 (https=) |
| CN (2) | CN104529883A (https=) |
| AP (1) | AP3336A (https=) |
| AR (1) | AR085615A1 (https=) |
| AU (1) | AU2012226473B8 (https=) |
| BR (1) | BR112013022536B1 (https=) |
| CA (1) | CA2828337C (https=) |
| CL (1) | CL2013002417A1 (https=) |
| CO (1) | CO6761338A2 (https=) |
| CR (1) | CR20130403A (https=) |
| CU (1) | CU20130117A7 (https=) |
| DO (1) | DOP2013000200A (https=) |
| EA (1) | EA024782B1 (https=) |
| EC (1) | ECSP13012928A (https=) |
| ES (1) | ES2626457T3 (https=) |
| GE (1) | GEP20156370B (https=) |
| GT (1) | GT201300213A (https=) |
| HK (1) | HK1209734A1 (https=) |
| IL (1) | IL228100A0 (https=) |
| MA (1) | MA34963B1 (https=) |
| MX (1) | MX341977B (https=) |
| NI (1) | NI201300077A (https=) |
| PE (1) | PE20140397A1 (https=) |
| PH (1) | PH12013501780A1 (https=) |
| SG (1) | SG192766A1 (https=) |
| TN (1) | TN2013000353A1 (https=) |
| TW (1) | TWI453197B (https=) |
| UA (1) | UA107423C2 (https=) |
| UY (1) | UY33936A (https=) |
| WO (1) | WO2012120397A1 (https=) |
| ZA (1) | ZA201306515B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5524215B2 (ja) | 2008-09-19 | 2014-06-18 | ファイザー・インク | 抗菌剤として有用なヒドロキサム酸誘導体 |
| WO2011073845A1 (en) | 2009-12-16 | 2011-06-23 | Pfizer Inc. | N-linked hydroxamic acid derivatives useful as antibacterial agents |
| ES2626457T3 (es) | 2011-03-07 | 2017-07-25 | Pfizer Inc. | Derivados de fluoro-piridinona útiles como agentes antibacterianos |
| CA2830866A1 (en) * | 2011-04-08 | 2012-10-11 | Pfizer Inc. | Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
| ES2526687T3 (es) | 2011-04-08 | 2015-01-14 | Pfizer Inc. | Derivados de isoxazol útiles como agentes antibacterianos |
| AR097617A1 (es) | 2013-09-13 | 2016-04-06 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos del 2h-indazol |
| WO2015085238A1 (en) * | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibitors of lpxc |
| EA030730B1 (ru) * | 2013-12-19 | 2018-09-28 | Идорсиа Фармасьютиклз Лтд | Антибактериальные производные 1h-индазола и 1h-индола |
| AR099612A1 (es) | 2014-03-04 | 2016-08-03 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona |
| EP3134401B1 (en) | 2014-04-22 | 2018-06-13 | Novartis AG | Isoxazoline hydroxamic acid derivatives as lpxc inhibitors |
| CA2948077A1 (en) * | 2014-05-16 | 2015-11-19 | Actelion Pharmaceuticals Ltd | Antibacterial quinazoline-4(3h)-one derivatives |
| CN106414429B (zh) | 2014-06-03 | 2020-01-03 | 爱杜西亚药品有限公司 | 吡唑化合物及其作为t型钙通道阻断剂的用途 |
| KR20170086079A (ko) | 2014-11-19 | 2017-07-25 | 액테리온 파마슈티칼 리미티드 | 항균성 벤조티아졸 유도체 |
| DK3233843T3 (da) | 2014-12-16 | 2019-11-18 | Novartis Ag | Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere |
| CN104876883B (zh) * | 2015-06-05 | 2017-11-28 | 安徽联创生物医药股份有限公司 | 抗失眠药物苏沃雷生中间体的合成方法 |
| AR105646A1 (es) * | 2015-08-11 | 2017-10-25 | Actelion Pharmaceuticals Ltd | Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida |
| AR105889A1 (es) | 2015-09-03 | 2017-11-22 | Actelion Pharmaceuticals Ltd | Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos |
| JP6941630B2 (ja) | 2016-06-14 | 2021-09-29 | ノバルティス アーゲー | 抗菌剤としての（ｒ）−４（５−（シクロプロピルエチニル）イソオキサゾール−３−イル）−ｎ−ヒドロキシ−２−メチル−２−（メチルスルホニル）ブタンアミドの結晶形 |
| MX388586B (es) | 2016-12-16 | 2025-03-20 | Idorsia Pharmaceuticals Ltd | Combinacion farmaceutica que comprende un bloqueador del canal de calcio de tipo t. |
| CA3050348A1 (en) | 2017-02-06 | 2018-08-09 | Idorsia Pharmaceuticals Ltd | A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes |
| JP2021518351A (ja) * | 2018-03-15 | 2021-08-02 | ファイザー・インク | 抗菌剤として有用なピリジノンおよびピリミジノンホスフェートおよびピリミジノンボロネート |
| WO2019175828A1 (en) * | 2018-03-15 | 2019-09-19 | Pfizer Inc. | Fluoro-pyridinone phosphates and boronates useful as antibacterial agents |
| CN110699312B (zh) * | 2019-11-28 | 2022-08-12 | 西北农林科技大学 | 一种猪种布鲁氏菌bi-1基因缺失菌株及其构建方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769461A (en) | 1986-09-16 | 1988-09-06 | American Home Products Corporation | Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents |
| US5110831A (en) | 1990-11-30 | 1992-05-05 | Du Pont Merck Pharmaceutical Company | Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors |
| DK1052984T3 (da) | 1998-02-07 | 2004-09-20 | Vernalis Oxford Ltd | Antibakterielle midler |
| GB9925470D0 (en) | 1999-10-27 | 1999-12-29 | Smithkline Beecham Plc | Novel compounds |
| JPWO2002074298A1 (ja) | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| ES2180456B1 (es) | 2001-07-20 | 2004-05-01 | Laboratorios S.A.L.V.A.T., S.A. | Isoxazoles sustituidos y su utilizacion como antibioticos. |
| ATE448784T1 (de) * | 2002-02-14 | 2009-12-15 | Pharmacia Corp | Substituierte pyridinone als modulatoren für p38 map kinase |
| KR101076018B1 (ko) | 2003-01-08 | 2011-10-21 | 유니버시티 오브 워싱톤 | 항균제 |
| GB0302431D0 (en) | 2003-01-30 | 2003-03-05 | Glaxo Group Ltd | Novel compounds |
| MX2007006961A (es) | 2004-12-10 | 2007-10-04 | Univ Emory | Analogos nucleosidos de ciclobutilo 2' y 3'-sustituidos para el tratamiento de infeccciones virales y proliferacion celular anormal. |
| WO2006118155A1 (ja) | 2005-04-27 | 2006-11-09 | Ishihara Sangyo Kaisha, Ltd. | ビフェニル誘導体又はその塩、並びにそれらを有効成分として含有する農園芸用殺菌剤 |
| US20060258691A1 (en) | 2005-05-13 | 2006-11-16 | Joseph Barbosa | Methods and compositions for improving cognition |
| JP2009520695A (ja) * | 2005-12-15 | 2009-05-28 | ヴィキュロン ファーマシューティカルズ インコーポレイテッド | 抗菌活性を有するｎ−ヒドロキシアミド誘導体 |
| WO2008045671A1 (en) | 2006-10-06 | 2008-04-17 | Janssen Pharmaceutica, N.V. | Matrix metalloprotease inhibitors |
| US7879911B2 (en) | 2007-02-01 | 2011-02-01 | Johnson Alan T | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning |
| JP5227304B2 (ja) | 2007-02-28 | 2013-07-03 | 大正製薬株式会社 | 新規なヒドロキサム酸誘導体 |
| WO2008115262A2 (en) | 2007-03-20 | 2008-09-25 | Curis, Inc. | Hsp90 inhibitors containing a zinc binding moiety |
| CN101239978A (zh) * | 2008-03-05 | 2008-08-13 | 南方医科大学 | 一种咪唑并吡啶类化合物 |
| WO2010017060A1 (en) * | 2008-08-04 | 2010-02-11 | Schering Corporation | Urea derivatives as antibacterial agents |
| JP5455913B2 (ja) | 2008-08-27 | 2014-03-26 | 大正製薬株式会社 | ナフチリジン−ｎ−オキシドを有する新規ヒドロキサム酸誘導体 |
| US8372885B2 (en) | 2008-09-17 | 2013-02-12 | Novartis Ag | Organic compounds and their uses |
| JP5524215B2 (ja) | 2008-09-19 | 2014-06-18 | ファイザー・インク | 抗菌剤として有用なヒドロキサム酸誘導体 |
| WO2010100475A1 (en) | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| WO2010147969A2 (en) * | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
| WO2010147975A1 (en) * | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
| WO2011073845A1 (en) | 2009-12-16 | 2011-06-23 | Pfizer Inc. | N-linked hydroxamic acid derivatives useful as antibacterial agents |
| ES2626457T3 (es) | 2011-03-07 | 2017-07-25 | Pfizer Inc. | Derivados de fluoro-piridinona útiles como agentes antibacterianos |
| CA2830866A1 (en) | 2011-04-08 | 2012-10-11 | Pfizer Inc. | Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
| ES2526687T3 (es) | 2011-04-08 | 2015-01-14 | Pfizer Inc. | Derivados de isoxazol útiles como agentes antibacterianos |
-
2012
- 2012-02-22 ES ES12709179.1T patent/ES2626457T3/es active Active
- 2012-02-22 GE GEAP201213215A patent/GEP20156370B/en unknown
- 2012-02-22 UA UAA201310358A patent/UA107423C2/ru unknown
- 2012-02-22 CA CA2828337A patent/CA2828337C/en active Active
- 2012-02-22 EP EP12709179.1A patent/EP2683689B1/en active Active
- 2012-02-22 PE PE2013002016A patent/PE20140397A1/es not_active Application Discontinuation
- 2012-02-22 AU AU2012226473A patent/AU2012226473B8/en active Active
- 2012-02-22 SG SG2013061643A patent/SG192766A1/en unknown
- 2012-02-22 PH PH1/2013/501780A patent/PH12013501780A1/en unknown
- 2012-02-22 MA MA36233A patent/MA34963B1/fr unknown
- 2012-02-22 BR BR112013022536-0A patent/BR112013022536B1/pt active IP Right Grant
- 2012-02-22 MX MX2013010276A patent/MX341977B/es active IP Right Grant
- 2012-02-22 CN CN201410611970.5A patent/CN104529883A/zh active Pending
- 2012-02-22 KR KR1020137026034A patent/KR101593288B1/ko not_active Expired - Fee Related
- 2012-02-22 EA EA201391072A patent/EA024782B1/ru not_active IP Right Cessation
- 2012-02-22 CN CN201280012230.9A patent/CN103443079B/zh active Active
- 2012-02-22 WO PCT/IB2012/050812 patent/WO2012120397A1/en not_active Ceased
- 2012-02-22 JP JP2013557190A patent/JP5620020B2/ja not_active Expired - Fee Related
- 2012-02-22 AP AP2013007074A patent/AP3336A/xx active
- 2012-03-05 AR ARP120100708A patent/AR085615A1/es unknown
- 2012-03-05 TW TW101107363A patent/TWI453197B/zh not_active IP Right Cessation
- 2012-03-06 UY UY0001033936A patent/UY33936A/es not_active Application Discontinuation
- 2012-03-07 US US13/414,057 patent/US8624034B2/en active Active
-
2013
- 2013-08-20 CR CR20130403A patent/CR20130403A/es unknown
- 2013-08-21 CL CL2013002417A patent/CL2013002417A1/es unknown
- 2013-08-22 IL IL228100A patent/IL228100A0/en unknown
- 2013-08-26 CU CU2013000117A patent/CU20130117A7/es unknown
- 2013-08-27 TN TNP2013000353A patent/TN2013000353A1/fr unknown
- 2013-08-29 ZA ZA2013/06515A patent/ZA201306515B/en unknown
- 2013-09-06 CO CO13211884A patent/CO6761338A2/es active IP Right Grant
- 2013-09-06 NI NI201300077A patent/NI201300077A/es unknown
- 2013-09-06 DO DO2013000200A patent/DOP2013000200A/es unknown
- 2013-09-06 GT GT201300213A patent/GT201300213A/es unknown
- 2013-10-07 EC ECSP13012928 patent/ECSP13012928A/es unknown
- 2013-10-31 US US14/068,956 patent/US8779148B2/en active Active
-
2014
- 2014-06-06 HK HK15110423.9A patent/HK1209734A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| ECSP20025899A (es) | Compuestos útiles para inhibir a cdk7 | |
| AR077629A1 (es) | Mimetico de smac | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
| MX2016006336A (es) | Compuestos pirazolopirimidina. | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
| CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
| CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| MX2016001480A (es) | Formulacion de inhibidores de syk. | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| CL2015001279A1 (es) | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
| CL2014001154A1 (es) | Compuestos derivados antibioticos de 2-oxo-oxazolidin-3,5-diilo de formula i; composicion farmaceutica; uso para la prevencion o tratamiento de una infeccion bacteriana. | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| NI201800071A (es) | Compuestos de isoindol |